A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report
- 27 July 2009
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (6), 978-983
- https://doi.org/10.1002/pbc.22209
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot StudyJournal of Clinical Oncology, 2008
- Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II TrialJournal of Clinical Oncology, 2005
- Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administrationBlood, 2004
- Monoclonal Antibodies in the Treatment of Chronic Lymphoid LeukemiasLeukemia & Lymphoma, 2004
- The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemiaJournal of Clinical Pathology, 2003
- Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received FludarabineJournal of Clinical Oncology, 2002
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002
- Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemiaBlood, 2002
- Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 2002
- High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1HBlood, 2001